Redcare Pharmacy's New Captain Brings Marketplace DNA — But the Stock's Course Remains Choppy

Peter Schmid von Linstow, a digital marketplace veteran, becomes Redcare Pharmacy CEO on Oct 1. Shares remain 34% below highs despite strong H1 growth.

When Peter Schmid von Linstow takes the helm at Redcare Pharmacy on October 1, he won't be arriving with a pharmacist's white coat in his luggage. His résumé reads more like a who's who of digital marketplaces — eBay, AutoScout24, Parship, and Visable — than a traditional healthcare operator's career path. That pedigree is precisely what makes the appointment both intriguing and, for some investors, unsettling.

The outgoing chief executive, Olaf Heinrich, is stepping down after three years at the top and will remain available to the company in an advisory capacity. Schmid von Linstow, who currently serves as deputy chairman of the supervisory board, already knows the business from the inside. His formal appointment was ratified at an extraordinary general meeting held last Tuesday, and since that gathering, the shares have slipped 2.3 percent.

A Friday Bounce That Masks a Longer Slide

The stock did manage a 4.7 percent advance on Friday, closing at EUR 59.65. Yet that single-session bounce does little to obscure the broader picture: the shares remain roughly 34 percent below their twelve-month high of EUR 90.05, sit nearly 8 percent under their 50-day moving average of EUR 64.66, and have shed 9.3 percent over the past year. With an annualized 30-day volatility of 51 percent, this is a stock that demands a strong stomach.

The market's nervousness is understandable when set against a curious disconnect. Operationally, Redcare is delivering. First-half 2026 revenue climbed 19 percent to EUR 1.7 billion, with the German prescription business — the Rx segment — surging 58 percent. Active customers grew 9 percent to 14.7 million. Management responded by lifting full-year guidance, targeting revenue growth of 15 to 17 percent and an EBITDA margin between 2.5 and 3 percent. That upgrade came roughly two weeks ago — and since then, the stock has given back 4.4 percent.

Jefferies Sees Weakness — But Relative Strength

Part of the explanation for the recent softness emerged on Thursday, when Jefferies reiterated its buy recommendation with a price target of EUR 97. The analysts acknowledged a weaker August in terms of active customer additions and app engagement, but crucially framed the slowdown as a sector-wide phenomenon rather than a Redcare-specific problem. In fact, they noted that Redcare fared better than rival DocMorris during the same period.

That nuanced take matters. It offers a plausible bridge between the company's strong reported results and the market's lukewarm reception — the August data points suggest momentum cooled at the operational coalface, even if the underlying growth narrative remains intact. For investors parsing the recent share-price weakness, Jefferies' framing suggests the drag is cyclical and industry-wide, not a reflection of Redcare losing competitive ground.

Platform Expertise Meets Pharmacy Regulation

The leadership transition adds another layer of uncertainty. Schmid von Linstow's background spans more than two decades of building and scaling digital platforms — the kind of businesses that thrive on network effects, commission models, and multi-sided marketplaces. That skill set could prove valuable if Redcare moves toward a more open platform strategy involving third-party sellers. Whether such a strategic shift is in the works, however, remains an open question.

There is a countervailing consideration: pharmaceutical mail-order is a heavily regulated arena, and Schmid von Linstow's lack of domain-specific experience could slow his early impact. The supervisory board's decision to propose his appointment for confirmation at an extraordinary general meeting on October 14 — shortly after he officially assumes the role — suggests a desire for swift formal endorsement.

The Watch List

Two dates now stand out for shareholders. October 1 marks the official handover, and the October 14 meeting will offer the first formal opportunity for investors to signal their view of the new leadership. In the meantime, the key operational question is whether August's softer customer metrics prove to be a seasonal dip or the start of a more persistent trend. With a market capitalization of EUR 1.14 billion, the gap between Jefferies' EUR 97 price target and the current share price reflects just how much conviction — or caution — the market is willing to attach to Redcare's next chapter.